AUTO8 — Initial data
Late 2026
The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.Source filing
AUTL biotech catalysts & pipeline
AUTOLUS THERAPEUTICS PLC · Data as of 2026-10-25
Upcoming catalysts
AUCATZYL (obecabtagene autoleucel) — Initial data
Q1 2027
Initial clinical data from BOBCAT Phase 1 trial in patients with progressive MS Q1 2027Source filing
AUCATZYL (obecabtagene autoleucel) — Full data
2H 2027
Phase 1 data from BOBCAT trial in patients with progressive MS 2H 2027Source filing
AUCATZYL (obecabtagene autoleucel) — Clinical data readout
Late 2027
Phase 2 data from CATULUS trial in patients with pediatric r/r B-ALL By year-end 2027Source filing
AUCATZYL (obecabtagene autoleucel) — Clinical data readout
in 2028
LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028.Source filing
AUCATZYL (obecabtagene autoleucel) — Conference presentation
Nov 10
Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster on November 10.Source filing